BeStock  
Stocks › Biotechnology › NTLA

Intellia Therapeutics NTLA

US equityMarket cap rank #2922BiotechnologyGene Editing
$10.00 +$0.48 (+5.04%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $10.00 +0.01%
Open$9.34
Prev close$9.52
Day range$9.30 – $10.40
Volume15.19M
Market cap$1.40B
P/E (TTM)–
Dividend yield–

NTLA Stock News

Headlines matching Intellia Therapeutics or the NTLA ticker, most recent first.

  • Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target PositiveBenzinga · 9 Sep 2026 · Related
  • H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25Market news · 9 Sep 2026 · Direct mention
  • Intellia Therapeutics | 8-K: Current reportSEC · 9 Sep 2026 · Related
  • Wedbush Initiates Intellia Therapeutics(NTLA.US) With Hold Rating, Announces Target Price $13Market news · 9 Sep 2026 · Direct mention
  • Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co.Dow Jones · 9 Sep 2026 · Related
  • Wedbush Adjusts Intellia Therapeutics Price Target to $13 From $12, Maintains Neutral RatingMT Newswires · 8 Sep 2026 · Related
  • Tracking Cathie Wood: Added over 110,000 shares of gene-editing firm NTLA, while continuing to reduce holdings and optimize portfolio allocation.牛牛名人追蹤 · 14 Sep 2026 · Direct mention
  • BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $17 NegativeMarket news · 8 Aug 2026 · Direct mention
  • CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $49Market news · 8 Aug 2026 · Direct mention
  • Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9Market news · 7 Aug 2026 · Direct mention
  • Evercore Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $24Market news · 7 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $25Market news · 7 Aug 2026 · Direct mention
  • JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $29Market news · 15 Aug 2026 · Direct mention
  • Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $15Market news · 10 Aug 2026 · Direct mention
  • Wolfe Research Downgrades Intellia Therapeutics(NTLA.US) to Sell Rating, Announces Target Price $9 NegativeMarket news · 16 Jul 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on NTLA.

Sign in to join the discussion.

Scroll to Top